Orforglipron for Early Type 2 Diabetes Management
This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy and safety as a once-daily monotherapy in adults whose type 2 diabetes is managed solely through diet and exercise. The findings demonstrate that orforglipron significantly reduces glycated hemoglobin levels and promotes body weight reduction over […]
Most on Wegovy a Year Later; Food Label Weight Stigma; Make Your Own GLP-1 Drugs?
(MedPage Today) — Over 60% of patients who started semaglutide (Wegovy) for obesity were still taking it a year later; but only one in seven stayed on the drug over 3 years, a pharmacy claims analysis from Prime Therapeutics found. Even when…
Ozempic-like drug significantly reduces frequency of chronic migraines in pilot study
Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment options, some migraine sufferers cannot find relief in available drugs. Others experience side effects that prevent the use of certain available migraine medications.
FDA Accepts Application for Oral Version of Wegovy
The US Food and Drug Administration (FDA) recently accepted a new drug application for oral semaglutide. If approved, it would be the first oral glucagon-like peptide-1 (GLP-1) receptor agonist authorized for long-term weight management. The 25-mg semaglutide pill would be marketed as Wegovy, the same name used for Novo Nordisk’s FDA-approved 2.4-mg semaglutide injection.
Popular weight-loss drugs may ease migraines too
A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Metabolic dysfunction–associated steatohepatitis (MASH), the progressive inflammatory form of MASLD, is now a leading cause of chronic liver disease worldwide. Driven by obesity and type 2 diabetes, MASH significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver failure. While public health interventions remain essential, therapeutic strategies targeting metabolic dysfunction, inflammation, and fibrosis are urgently […]
Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement
TUESDAY, July 1, 2025 — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study published online June 24 in the Annals of…
This Ozempic-Like Drug Slashed Migraines by Half in a Small Trial
The drug helped people who couldn’t get relief from existing treatments. It starts with flashes of light. Zig-zag lines float across your vision. You feel a slight tingling in your cheeks and limbs. Then comes a stabbing headache so intense you forget everything—what you were doing, where you are, and how to compose yourself. Scientists […]
Could China’s New Ozempic-like Drugs Beat Out Current Weight-Loss Medications?
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes
STAT+: Pharmalittle: We’re reading about Novo’s Wegovy launch gaffes, a former Pfizer exec’s subpoena, and more
Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot campus than from our ritual cup of stimulation; our choice today is marshmallow magic, by the way. But this is to be expected at this time of year, yes? In […]